We are live on !
Find out more
Eversept Partners Portfolio holdings
AUM
$1.93B
Turnover
41.06%
1-Year Est. Return
160.8%
This Fund
S&P 500
This Quarter Est. Return
+7.72%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$357M
AUM Growth
+$14.3M
(+4.2%)
Cap. Flow
-$378K
Cap. Flow % of AUM
Cap. Flow %
-0.11%
Top 10 Holdings %
Top 10 Hldgs %
60.48%
Holding
73
New
21
Increased
19
Reduced
16
Closed
11
Avg Time Held
Equity + Options
0.6
years
Top 10 Avg Time Held
Equity + Options
0.8
years
Top 20 Avg Time Held
Equity + Options
0.7
years
Avg Time Held Equity only
0.7
years
Top 10 Avg Time Held Equity only
0.8
years
Top 20 Avg Time Held Equity only
0.7
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
The Ensign Group
ENSG
|
+$7.79M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
+$6.69M |
| 3 |
Audentes Therapeutics, Inc
BOLD
|
+$6.13M |
| 4 |
Illumina
ILMN
|
+$5.94M |
| 5 |
Centene
CNC
|
+$4.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NUVA
NuVasive, Inc.
NUVA
|
+$14.1M |
| 2 |
Amarin Corp
AMRN
|
+$9.2M |
| 3 |
Sarepta Therapeutics
SRPT
|
+$8.15M |
| 4 |
ABMD
Abiomed Inc
ABMD
|
+$7.81M |
| 5 |
AERI
Aerie Pharmaceuticals
AERI
|
+$5.45M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 82.49% |
| 2 | Industrials | 9.51% |
| 3 | Financials | 4.31% |
| 4 | Miscellaneous | 1.99% |
| 5 | Real Estate | 1.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
MacroGenics
MGNX
$207M
| $3.23M | 0.91% |
+190,623
| New | +$3.27M |
2019 Q2
0 quarters
|
|
|
HSKA
27
DELISTED
Heska Corp
HSKA
| $2.97M | 0.83% |
34,924
+28,244
| +423% | +$2.2M |
2019 Q1
1 quarter
|
|
28
DELISTED
Apellis Pharmaceuticals
APLS
| $2.97M | 0.83% |
117,309
+12,960
| +12% | +$264K |
2018 Q2
4 quarters
|
|
|
MYOK
29
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $2.84M | 0.8% |
56,652
+21,600
| +62% | +$1.05M |
2019 Q1
1 quarter
|
|
30
Elevance Health
ELV
$92.9B
| $2.82M | 0.79% |
+10,000
| New | +$2.73M |
2019 Q2
0 quarters
|
|
31
Humana
HUM
$49.6B
| $2.66M | 0.74% |
+10,000
| New | +$2.54M |
2019 Q2
0 quarters
|
|
|
32
Sarepta Therapeutics
SRPT
$1.81B
| $2.52M | 0.7% |
16,554
-67,020
| -80% | -$8.15M |
2018 Q2
4 quarters
|
|
|
GHDX
33
DELISTED
Genomic Health, Inc.
GHDX
| $2.23M | 0.63% |
+38,403
| New | +$2.27M |
2019 Q2
0 quarters
|
|
34
Xenon Pharmaceuticals
XENE
$3.24B
| $2.21M | 0.62% |
224,340
| – | – |
2018 Q3
3 quarters
|
|
35
PTC Therapeutics
PTCT
$4.94B
| $2.19M | 0.61% |
48,600
-52,000
| -52% | -$2.05M |
2019 Q1
1 quarter
|
|
|
MDCO
36
DELISTED
Medicines Co
MDCO
| $2.09M | 0.58% |
57,200
-19,000
| -25% | -$620K |
2019 Q1
1 quarter
|
|
37
Collegium Pharmaceutical
COLL
$755M
| $1.85M | 0.52% |
+141,000
| New | +$1.89M |
2019 Q2
0 quarters
|
|
|
ZGNX
38
PUT
DELISTED
Zogenix, Inc.
ZGNX
| $1.74M | 0.49% |
+36,400
| New | +$1.47M |
2019 Q2
0 quarters
|
|
|
BDSI
39
DELISTED
BioDelivery Sciences International, Inc.
BDSI
| $1.66M | 0.46% |
+356,274
| New | +$1.66M |
2019 Q2
0 quarters
|
|
|
TLGT
40
DELISTED
Teligent, Inc
TLGT
| $1.63M | 0.46% |
258,488
+1,000
| +0.4% | +$8.15K |
2017 Q4
6 quarters
|
|
41
Sabra Healthcare REIT
SBRA
$4.94B
| $1.55M | 0.43% |
+78,600
| New | +$1.53M |
2019 Q2
0 quarters
|
|
42
Omega Healthcare
OHI
$13.8B
| $1.52M | 0.43% |
+41,400
| New | +$1.51M |
2019 Q2
0 quarters
|
|
43
LTC Properties
LTC
$2.35B
| $1.51M | 0.42% |
+33,027
| New | +$1.5M |
2019 Q2
0 quarters
|
|
44
CareTrust REIT
CTRE
$8.64B
| $1.5M | 0.42% |
62,464
+21,200
| +51% | +$514K |
2017 Q4
6 quarters
|
|
45
BioCryst Pharmaceuticals
BCRX
$1.99B
| $1.3M | 0.36% |
342,460
-70,416
| -17% | -$424K |
2017 Q4
6 quarters
|
|
|
IVC
46
DELISTED
Invacare Corporation
IVC
| $1.09M | 0.31% |
210,283
+131,202
| +166% | +$855K |
2017 Q4
6 quarters
|
|
47
DELISTED
Affimed
AFMD
| $925K | 0.26% |
32,217
| – | – |
2018 Q1
5 quarters
|
|
|
PRVB
48
DELISTED
Provention Bio, Inc. Common Stock
PRVB
| $891K | 0.25% |
+73,661
| New | +$401K |
2019 Q2
0 quarters
|
|
49
DELISTED
OptiNose
OPTN
| $744K | 0.21% |
+7,007
| New | +$923K |
2019 Q2
0 quarters
|
|
|
EIGR
50
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $739K | 0.21% |
2,324
| – | – |
2019 Q1
1 quarter
|
|
Similar funds
Eversept Partners's Q2 2019 Portfolio in Review
As of Q2 2019, Eversept Partners held 73 positions worth $357M, up 4.2% from $343M the previous quarter. Its ten largest holdings account for 60% of the portfolio.
Eversept Partners's Q2 2019 filing shows 21 new, 19 increased, 16 reduced and 11 closed positions. Its largest new stake was Alnylam Pharmaceuticals: 87,140 shares worth $6.32M. The largest sale was NuVasive, Inc., an estimated $14.1M.
By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 86% a quarter earlier, followed by Industrials and Financials.
- Eversept Partners's largest Q2 2019 buy was Alnylam Pharmaceuticals: 87,140 shares worth $6.32M.
- Eversept Partners added most to The Ensign Group in Q2 2019, an estimated $7.79M increase.
- Eversept Partners's biggest Q2 2019 reduction was NuVasive, Inc., cutting an estimated $14.1M.
- Eversept Partners fully exited Abiomed Inc in Q2 2019, selling an estimated $7.81M.
- Eversept Partners's ten largest holdings make up 60% of its $357M portfolio in Q2 2019.
- Eversept Partners opened 21 new positions and closed 11 in Q2 2019.
- Eversept Partners's portfolio value rose 4.2% quarter-over-quarter to $357M.
Based on Eversept Partners's 13F filing for Q2 2019, filed 13 Aug 2019.